| 描述 | CD303 (BDCA-2) antibodies have been used, for example, to identify, characterize, and enumerate plasmacytoid dendritic cells in whole blood of healthy and HIV-infected individuals, and for analyzing the role of DC-SIGN in HIV infection and transmission.7,11 Furthermore, CD303 (BDCA-2) antibodies were used to identify and enumerate plasmacytoid dendritic cells in blood and bone marrow samples before and after hematopoietic stem cell mobilization8 or transplantation10. CD303 (BDCA-2) antibodies were also used for immunohistochemical staining, for example to identify plasmacytoid dendritic cells in tissue sections from patients with different inflammatory skin diseases.5,12,13Clone AC144 recognizes the the CD303 (BDCA-2) antigen1,3 which is expressed on human plasmacytoid dendritic cells in blood, lymphoid (e.g. tonsils and bone marrow) and non-lymphoid tissue.3,6 Specific expression allows direct identification of plasmacytoid dendritic cells using just one marker.1–11 CD303 (BDCA-2)+ plasmacytoid dendritic cells in blood and bone marrow are CD11c–, CD123high, CD4+, Lin–, CD45RA+, CD304 (BDCA-4/Neuropilin-1)+, CD141 (BDCA-3)low, CD1c (BDCA-1)–, CD14–, and CD2–. They express neither myeloid lineage markers (CD13, CD33) nor Fc receptors (CD32, CD64, FcRI).1,6 CD303 (BDCA-2) is strongly expressed on freshly isolated plasmacytoid dendritic cells but down-regulated within 48 hours of culturing.1 Unlike CD304 (BDCA-4/Neuropilin-1), CD303 (BDCA-2) is not detectable on ex vivo generated monocyte-derived or hematopoietic precursor cell-derived CD1a+ dendritic cells.1,9The CD303 (BDCA-2) antigen is a novel type II transmembrane C-type lectin.3 Remarkably, plasmacytoid dendritic cells can take up ligands via CD303 (BDCA-2), then process and present the ligands to T cells.1,3 Unlike binding of antibodies to CD304 (BDCA-4), binding of antibodies to CD303 (BDCA-2) inhibits type I IFN production, which is induced in plasmacytoid dendritic cells by, for example, the influenza virus.3,6 |
